Search clinical trials for: Rituximab plus cyclophosphamide placebo (rituximab group)

Total 831 results

Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Lymphoma

United States
Swiss Group for Clinical Cancer Research

Completed

PET Scans in Patients With Diffuse Large B-Cell Lymphoma Receiving Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

Lymphoma

Switzerland, Italy
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Lymphoma

United States
Azienda Socio Sanitaria Territoriale degli Spedali...

Completed

High Dose Therapy and Peripheral Blood Stem Cell Transplantation in HIV Related Non Hodgkin Lymphoma (NHL) at High Risk (HDT-HIV)

HIV Infections | HIV-related Lymphoma

Italy
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma

Lymphoma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma

Lymphoma
British Columbia Cancer Agency
National Cancer Institute (NCI)

Completed

Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Lymphoma

Canada, United States
David Bond, MD
Bristol-Myers Squibb

Active, not recruiting

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Diffuse Large B-Cell Lymphoma | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | Transformed Non-Hodgkin Lymphoma | Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage... and other conditions

United States
Northwestern University
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

Diffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma... and other conditions

United States
Li Zhiming
Antengene Corporation

Recruiting

Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

DLBCL Germinal Center B-Cell Type

China
Medstar Health Research Institute

Withdrawn

Rituximab Followed by Combination Chemotherapy in Treating Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma

Lymphoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Lymphoma

United States
Mansoura University

Unknown

Risk Adapted Therapy in Diffuse Large B Cell Lymphoma

Large B Cell Lymphoma

Egypt
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States, Puerto Rico
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Lymphoma | Leukemia

United States
Centre Antoine Lacassagne

Completed

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Lymphoma

France
National Cancer Institute (NCI)

Completed

Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Lymphoma

United States, Australia, South Africa, Peru, Puerto Rico
Assistance Publique - Hôpitaux de Paris

Completed

Rituximab in Systemic Sclerosis (RECOVER)

Systemic Sclerosis

France
The First Hospital of Jilin University
CSPC Ouyi Pharmaceutical Co., Ltd.

Not yet recruiting

The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.

Diffuse Large B-cell Lymphoma

China
University Hospital, Strasbourg, France

Completed

Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis (ROC)

Rheumatoid Arthritis

France, Monaco
M.D. Anderson Cancer Center

Completed

Treatment of Macroglobulinemic Lymphoma With 2CdA, Cyclophosphamide and Rituximab

Lymphoma

United States
St. Jude Children's Research Hospital

Active, not recruiting

CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

B-ALL | T-ALL | AML/MDS | BPDCN

United States
Peking University People's Hospital
Beijing Hospital

Unknown

Treatment of ITP With Rituximab and / or Accutane

Immune Thrombocytopenia
Thomas Jefferson University
National Cancer Institute (NCI)

Recruiting

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Recurrent Indolent Adult Non-Hodgkin...

United States
University of Nebraska
National Cancer Institute (NCI)

Completed

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

Lymphoma

United States
Gustave Roussy, Cancer Campus, Grand Paris
Children's Oncology Group

Unknown

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

B-cell Non Hodgkin Lymphoma | Mature B-cell Leukemia Burkitt-type

Belgium, France, United Kingdom, Netherlands, Canada, Hungary, Italy, Poland, Spain, China
University of Athens
Naval Hospital, Athens; General Hospital of Nikaia "Saint Panteleimon"

Recruiting

Vitamin C, Hydrocortisone and Thiamine for Septic Shock (CORVICTES)

Shock, Septic

Greece
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma

Lymphoma

United States
University Hospital Inselspital, Berne

Completed

Peg-Granulocyte-Colony Stimulating Factor (GCSF) for Coronary Collateral Growth in Coronary Artery Disease Patients

Coronary Artery Disease

Switzerland
Chulalongkorn University

Unknown

The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients

Peritoneal Membrane Failure

Thailand
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma

China
Seagen Inc.
Genentech, Inc.

Terminated

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

United States, France, Spain, Belgium, Australia, Germany, Poland, Italy, Czech Republic, Hungary
Massachusetts General Hospital
Gilead Sciences

Withdrawn

Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis

Fatigue | Multiple Sclerosis, Relapsing-Remitting

United States
Singapore General Hospital
Janssen-Cilag Ltd.

Completed

Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma (SGH652)

Diffuse Large B-Cell Lymphoma

Singapore
University of Athens

Recruiting

Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock (CORVICTES-ΥΜ)

Septic Shock

Greece
Eastern Cooperative Oncology Group
National Cancer Institute (NCI); Cancer and Leukemia Group B; North Central Cancer... and other collaborators

Completed

Combination Chemotherapy in Treating Women With Breast Cancer

Breast Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

Lymphoma

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia

Myeloid Diseases

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer

Breast Cancer

United States
David Rizzieri
Eleos, Inc.

Terminated

EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Lymphoma, Small Lymphocytic | Leukemia, Lymphocytic, Chronic

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Sun Yat-sen University

Recruiting

Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer

Breast Cancer

China
University of Rochester

Recruiting

A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma

DLBCL

United States
University of Southampton

Terminated

Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma

Lymphoma

United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

Lymphoproliferative Disorder

Canada, United States, Australia, New Zealand
Northside Hospital, Inc.
Blood and Marrow Transplant Group of Georgia

Terminated

Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma and other conditions

United States
French Innovative Leukemia Organisation
Hoffmann-La Roche

Completed

Treatment of Mantle Cell Lymphoma at Diagnosis for Patients Under 65 Years

Mantle Cell Lymphoma

France
National Cancer Institute (NCI)

Not yet recruiting

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell | B-Cell Chronic Lymphocytic Leukemia | B-Lymphocytic Leukemia, Chronic

United States
Dana-Farber Cancer Institute
Secura Bio, Inc.

Active, not recruiting

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

Chronic Lymphocytic Leukemia

United States

Search clinical trials for: Rituximab plus cyclophosphamide placebo (rituximab group)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations